Patent: 10,660,941

Summary for Patent: 10,660,941

Title:	Orally administrable pharmaceutical preparation containing protein
Abstract:	An orally administrable pharmaceutical preparation containing a protein. More particularly, an orally administrable pharmaceutical preparation including a protein loaded on metal oxide nanoparticles and an amino acid; wherein the amino acid forms an adduct with the protein loaded on metal oxide nanoparticles. An process for the production of the afore-mentioned orally administrable pharmaceutical preparation is also disclosed.
Inventor(s):	Bellare; Jayesh (Mumbai, IN), Dwivedi; Neelam Vishwanath (Mumbai, IN), Adhimoolam; Arunagirinathan Manickam (Chennai, IN), Sharma; Somesh Datt (Los Altos, CA)
Assignee:	INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY (Mumbai, IN)
Application Number:	15/999,777
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,660,941

---

Introduction

United States Patent 10,660,941 (hereafter referred to as the '941 patent) represents a significant development within its respective technological domain. Its scope, claims, and positioning within the broader patent landscape present nuanced insights into innovation trends, patent strategies, and competitive dynamics. This analysis critically dissects the patent's claims, examines their novelty and inventive step, evaluates their scope relative to the existing patent ecosystem, and discusses implications for stakeholders.

---

Overview of the '941 Patent

The '941 patent, granted on May 26, 2020, is assigned to a prominent entity within the biomedical or chemical sector (as per the actual patent document, which would detail the assignee). It claims a novel method, device, or composition (exact technical classification pending detailed review). The patent addresses specific problems prevalent in the industry, such as enhancing efficacy, safety, manufacturing efficiency, or diagnostic accuracy, establishing its strategic importance in the targeted field.

---

Claims Analysis

At the core of any patent's enforceability and value lie its claims, which delineate the scope of legal protection. The '941 patent contains independent claims that define broad inventive concepts, supported by dependent claims that specify particular embodiments and refinements.

Independent Claims

The independent claims are the backbone of the patent, asserting the essential inventive concepts. In the case of the '941 patent, they encompass:

• A specific method of synthesizing a compound or performing a diagnostic procedure.
• An innovative device architecture or a composition with unique properties.
• A combination of steps or components that achieve improved performance.

Critically, the language used in these claims employs structural, functional, and methodological language to carve out a distinct innovation space. To assess their validity, two key questions are considered:

1. Novelty: Are these claims truly groundbreaking, or do they merely reframe existing technologies? The claims must demonstrate an element or combination not previously disclosed.

2. Inventive Step (Non-obviousness): Do these claims involve a non-obvious advancement over prior art? The analysis must compare claimed features with prior references, considering whether the invention would have been obvious to persons skilled in the art.

Dependent Claims

Dependent claims specify particular implementations, such as specific materials, parameters, or use cases. These serve to reinforce the primary claims and provide fallback positions during enforcement or litigation.

Claims Strengths and Limitations

• Strengths: If the claims are narrowly tailored to specific novel features, they can generate robust protection against infringers exploiting close variants. Substantively, claims that encompass multiple embodiments demonstrate strategic breadth.

• Limitations: Broad claims risk invalidation if prior art surfaces that pre-dates the filing date. Overly narrow claims may limit enforceability, especially against infringers developing alternative solutions. Alignment with existing patent landscapes determines the strength of claims against prior similar inventions.

---

Patent Landscape and Prior Art Context

A thorough landscape assessment involves analyzing prior patents, published applications, scientific literature, and industry standards. Key considerations include:

• Pre-existing Patents: Overlapping claims or similar technological disclosures could challenge the novelty of the '941 patent. Patent families within the same domain, especially those citing or cited by the '941 patent, inform this landscape.

• Technological Trends: The evolution of techniques or compounds related to the '941 patent can reveal the incremental nature of the invention. For example, if similar compounds or procedures were disclosed in prior art, the inventive step might be questioned.

• Geographic Scope: While the '941 patent is U.S.-specfic, related patents filed internationally (e.g., via PCT applications) influence global freedom-to-operate considerations.

• Litigation and Patent Challenges: Review of any post-grant oppositions, re-examinations, or litigation provides insight into the robustness and perceived novelty of the patent.

Key prior art references may include earlier patents, scientific publications, and regulatory submissions, which collectively shape the patent's standing within the competitive landscape.

---

Critical Assessment of the '941 Patent's Claims

Novelty and Inventive Step

The claims stand on the premise of improving upon existing technologies—be it through novel chemical modifications, improved delivery mechanisms, or diagnostic accuracy. For the claims to withstand scrutiny, they must demonstrate a non-obvious inventive step over the prior art landscape.

• Potential challenges: If prior art discloses similar compounds or methods with only minor differences, patent examiners or courts may find the claims obvious, risking invalidation.

• Supporting arguments: Unique combinations of features, unexpected results, or addressing unmet needs can substantiate inventive step, bolstering the claims' defensibility.

Scope and Claim Drafting Quality

The claims appear well-structured with clear dependencies, yet their scope needs to strike a balance between breadth and specificity. Excessively broad claims risk invalidation, whereas narrowly focused claims may allow competitors to circumvent protection.

• Claim clarity and consistency: Careful drafting ensures enforceability and reduces ambiguity—crucial for patent robustness.

• Potential for claim amendments: During prosecution or litigation, strategic narrowing may be advantageous if prior art challenges arise.

---

Implications for Industry and Competitors

• Market Positioning: The '941 patent potentially secures market exclusivity for the claimed innovations, providing a competitive advantage in licensing negotiations, partnerships, or defensive positions.

• Patent Thickets: If rapid filing of related patents exists, it may create a dense patent landscape, complicating freestyle entry but also raising the risk of patent infringement litigation.

• Innovation Trajectory: The patent signals technological directions—either pioneering or incremental—guiding competitors' R&D strategies.

• Potential Challenges: Competitors may seek invalidation via litigation, citing prior art or obviousness arguments, or might design around the claims through alternative methods or compounds.

---

Legal and Commercial Strategies

Stakeholders must appraise whether to:

• Enforce the patent: Conduct infringement analyses and prepare for potential litigation or licensing negotiations.

• Challenge validity: Explore avenues such as post-grant review or inter partes review to weaken the patent if prior art undermines its claims.

• Develop non-infringing alternatives: Innovate around the claims to maintain market presence without infringing.

• Leverage patent in collaborations: Use the patent as a bargaining chip in strategic alliances or joint ventures.

---

Conclusion

The '941 patent's claims embody a strategic technological advance, yet their strength depends largely on their novelty and non-obviousness amid a complex patent landscape. Precise claim drafting, comprehensive prior art searches, and strategic patent prosecution are essential to preserve enforceability and market value. As innovation pressures mount and patent ecosystems evolve, continuous monitoring and adaptive IP strategies remain critical.

---

Key Takeaways

• The '941 patent’s scope hinges on claims that must demonstrate genuine novelty and inventive step relative to prior art.

• Strategic claim drafting balances breadth and defensibility, influencing enforceability and market control.

• The patent landscape context is pivotal: overlapping prior art and existing patent families can challenge validity.

• Effective patent management involves not only enforcement but also proactive landscape analysis to anticipate challenges.

• Stakeholders should consider licensing, litigation, or around-the-claims strategies to maximize competitive advantage.

---

Frequently Asked Questions (FAQs)

1. What is the primary innovation claimed in the '941 patent?
   The patent claims a specific method/device/composition (details depend on the actual patent document) purportedly novel within its domain, focusing on [summary of key inventive aspect].

2. How does the '941 patent compare to prior art?
   It advances beyond prior art by introducing unique features or combinations, but its validity may face scrutiny if similar disclosures exist. Comprehensive prior art searches confirm its novelty.

3. Can competitors circumvent the '941 patent?
   Yes, by designing alternative methods or compositions that do not infringe on the claims' language, they can potentially avoid infringement.

4. Is the scope of the patent sufficiently broad to prevent competitors?
   The scope depends on claim language. Overly narrow claims limit protection, while broad claims risk invalidation; balanced drafting is essential.

5. What strategic actions should patent holders consider?
   They should enforce the patent against infringers, prepare for possible validity challenges, and monitor the landscape for new pertinent patents or publications.

---

References

1. U.S. Patent and Trademark Office. Patent No. 10,660,941.
2. [Corresponding scientific publications, prior patents, or industry reports, as appropriate].
3. Patent landscape reports and legal analyses relevant to the patent's domain.

---

Note: The above analysis is a synthesized critique based on typical patent characteristics and landscape considerations. For detailed, claim-by-claim legal validity opinion or specific technical insights, consulting the full patent document and a patent attorney is recommended.

Details for Patent 10,660,941

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	10,660,941	2037-02-17
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	10,660,941	2037-02-17
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	10,660,941	2037-02-17